We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+8.88%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$4.2B
AUM Growth
+$12M
Cap. Flow
-$165M
Cap. Flow %
-3.93%
Top 10 Hldgs %
34.34%
Holding
127
New
6
Increased
36
Reduced
16
Closed
4

Top Buys

Rank Stock Value
1
HUM icon
Humana
HUM
+$21.9M
2
BSX icon
Boston Scientific
BSX
+$14M
3
MRUS
Merus
MRUS
+$10.5M
4
AGL icon
Agilon Health
AGL
+$8.99M
5
BPMC
Blueprint Medicines
BPMC
+$8.35M

Top Sells

Rank Stock Value
1
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
+$111M
2
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$40.3M
3
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$25.9M
4
PEN icon
Penumbra
PEN
+$20.7M
5
UNH icon
UnitedHealth
UNH
+$19.6M

Sector Composition

Rank Sector Weight
1 Healthcare 97.12%
2 Consumer Staples 1.04%
3 Industrials 0.9%
4 Financials 0.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BHVN icon
76
Biohaven
BHVN
$2.2B
$9.61M 0.23%
401,624
-283,999
-41% -$4.89M
MREO
77
Mereo BioPharma
MREO
$44.9M
$9.3M 0.22%
7,042,391
+797,494
+13% +$925K
PLRX icon
78
Pliant Therapeutics
PLRX
$65M
$8.9M 0.21%
491,221
– –
ICVX
79
DELISTED
Icosavax, Inc. Common Stock
ICVX
$8.62M 0.21%
868,409
+3,899
+0.5% +$31.2K
LUNG icon
80
Pulmonx
LUNG
$97.5M
$8.55M 0.2%
652,400
– –
RLAY icon
81
Relay Therapeutics
RLAY
$4.41B
$8.47M 0.2%
673,966
– –
OKUR
82
OnKure Therapeutics
OKUR
$165M
$7.5M 0.18%
114,319
– –
GH icon
83
Guardant Health
GH
$22.7B
$7.16M 0.17%
200,000
– –
ANAB icon
84
AnaptysBio
ANAB
$1.65B
$6.95M 0.17%
341,637
-234,963
-41% -$4.76M
MGNX icon
85
MacroGenics
MGNX
$257M
$6.01M 0.14%
1,123,096
– –
SPRB
86
Spruce Biosciences
SPRB
$126M
$5.87M 0.14%
36,375
– –
NVCR icon
87
NovoCure
NVCR
$2.04B
$5.19M 0.12%
125,000
– –
AUPH icon
88
Aurinia Pharmaceuticals
AUPH
$2.07B
$4.64M 0.11%
479,540
– –
VIGL
89
DELISTED
Vigil Neuroscience
VIGL
$4.44M 0.11%
471,958
– –
KRYS icon
90
Krystal Biotech
KRYS
$9.74B
$4.1M 0.1%
+34,901
New +$3.56M
THRX
91
DELISTED
Theseus Pharmaceuticals, Inc. Common Stock
THRX
$4.08M 0.1%
437,329
– –
NVAX icon
92
Novavax
NVAX
$1.29B
$3.99M 0.09%
536,700
+1,300
+0.2% +$10.2K
PRTK
93
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$3.83M 0.09%
1,734,037
– –
XLO icon
94
Xilio Therapeutics
XLO
$60.5M
$3.77M 0.09%
102,911
– –
BEAM icon
95
Beam Therapeutics
BEAM
$2.83B
$3.56M 0.08%
111,430
– –
CYPH
96
Cypherpunk Technologies Inc
CYPH
$73.4M
$3.36M 0.08%
1,074,517
+608,998
+131% +$3.06M
SLRN
97
DELISTED
ACELYRIN
SLRN
$2.97M 0.07%
+141,876
New +$2.9M
FATE icon
98
Fate Therapeutics
FATE
$329M
$2.91M 0.07%
612,215
– –
DSGN icon
99
Design Therapeutics
DSGN
$894M
$2.9M 0.07%
460,391
– –
BDTX icon
100
Black Diamond Therapeutics
BDTX
$115M
$2.84M 0.07%
+563,233
New +$1.15M
1 2 3
4
5

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q2 2023 Portfolio in Review

As of Q2 2023, Rock Springs Capital Management held 127 positions worth $4.2B, up 0.29% from $4.19B the previous quarter. Its ten largest holdings account for 34% of the portfolio.

Rock Springs Capital Management withdrew a net $165M in Q2 2023, closing 4 positions and reducing 16 holdings. Its most notable exit was Prometheus Biosciences, Inc. Common Stock, an estimated $111M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 97% a quarter earlier, followed by Consumer Staples and Industrials.

Against the trend, Rock Springs Capital Management opened a new position in Boston Scientific worth $14.5M.

  • Rock Springs Capital Management's largest Q2 2023 buy was Boston Scientific: 267,500 shares worth $14.5M.
  • Rock Springs Capital Management added most to Humana in Q2 2023, an estimated $21.9M increase.
  • Rock Springs Capital Management's biggest Q2 2023 reduction was Madrigal Pharmaceuticals, cutting an estimated $40.3M.
  • Rock Springs Capital Management fully exited Prometheus Biosciences, Inc. Common Stock in Q2 2023, selling an estimated $111M.
  • Rock Springs Capital Management's ten largest holdings make up 34% of its $4.2B portfolio in Q2 2023.
  • Rock Springs Capital Management opened 6 new positions and closed 4 in Q2 2023.
  • Rock Springs Capital Management's portfolio value rose 0.29% quarter-over-quarter to $4.2B.

Based on Rock Springs Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.